Evinacumab – one year of experience in patients with homozygous familial hypercholesterolemia: case reports

Czech version

Authors: Lukáš Zlatohlávek ¹; Jana Beňová Becherová ¹; Jaroslav A. Hubáček ^1,2
Authors‘ workplace: Centrum preventivní kardiologie, III. interní klinika – klinika endokrinologie a metabolismu 1. LF UK a VFN v Praze ¹; Centrum experimentální medicíny IKEM, Praha ²
Published in: AtheroRev 2025; 10(3): 183-187
Category:

Overview

In this article, we present three case reports of patients with homozygous familial hypercholesterolemia who, after reaching the maximum possible pharmacological intervention with statins, ezetimibe, and PCSK9i, were given an additional drug –⁠ evinacumab. The article documents the course of therapy and decreases in LDL-cholesterol (LDL-C) levels, with patients experiencing reductions in LDL-C levels of up to 84.1%, 84.5%, and 93.2%, respectively, compared to baseline values. Patients were monitored for approximately 9 months, during which no clinically or laboratory-significant adverse effects associated with evinacumab treatment were reported.

Keywords:

LDL-cholesterol – evinacumab – homozygous familial hypercholesterolemia

Sources

Akioyamen LE, Genest J, Shan SD et al. Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis. BMJ Open 2017; 7(9): e016461. Dostuné z DOI: <http://doi: 10.1136/bmjopen-2017-016461>.

Sturm AC, Knowles JW, Gidding SS et al. Clinical Genetic Testing for Familial Hypercholesterolemia: JACC Scientific Expert Panel. JACC 2018; 72(6): 662–680. Lancet 2021; 398(10318): 1873–1886. Dostupné z DOI: <http://doi: 10.1016/j.jacc.2018.05.044>.

Freiberger T et al. Aktualizace 2023 konsenzu Evropské společnosti pro aterosklerózu o homozygotní familiární hypercholesterolemii: nová léčba a klinická doporučení. AtheroRev 202š; 8(3): 135–144.

Blaha V. Evinakumab v léčbě homozygotní familiární hypercholesterolemie: data z reálné klinické praxe a kazuistika. AtheroRev 2025; 10(2): 111–115.